文献速递重症综合管理与镇静镇痛

黄柏酮抗脓毒症潜在靶点的优化与鉴定

[Optimization and identification of potential targets of obacunone against sepsis].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2024-01-01
一句话结论黄柏酮通过调控凝血、炎症、免疫及器官保护相关靶点,可能成为脓毒症的潜在治疗分子。

本研究利用TCMSP分析黄柏酮的药理参数与分子特征,并用SwissTargetPrediction和DRAR-CPI软件(Z'-score < -0.5)筛选抗脓毒症潜在靶点,再通过OMIM、CTD和TTD数据库筛选抗脓毒症靶点,最后用分子对接鉴定。结果显示黄柏酮口服生物利用度为81.58%,类药性为0.57;共筛选出242个潜在靶点,其中13个与脓毒症直接相关;分子对接鉴定出CTSG、CASP1、S100A9、PROC、MAPK1、G6PD、IL-10、MIF、C5AR1、CASP3、CXCR2、F2R、NAMPT为潜在抗脓毒症靶点,并给出各自自由结合能。结论提示黄柏酮可通过调控PROC和F2R抑制凝血、改善炎症反应,调控MIF、S100A9、G6PD和IL-10参与免疫反应,调控CTSG、CASP1、MAPK1、C5AR1和CASP3保护脓毒症损伤器官,调控CXCR2减少中性粒细胞过度迁移至炎症部位、减轻组织损伤,调控NAMPT改善细胞能量状态、减少氧化应激、保护细胞免受损伤。

要点

  • 黄柏酮口服生物利用度为81.58%,类药性为0.57,提示成药性良好。
  • 经SwissTargetPrediction和DRAR-CPI软件(Z'-score < -0.5)共筛选出242个潜在靶点,其中13个与脓毒症直接相关。
  • 分子对接鉴定出CTSG、CASP1、S100A9、PROC、MAPK1、G6PD、IL-10、MIF、C5AR1、CASP3、CXCR2、F2R、NAMPT为黄柏酮抗脓毒症的潜在靶点。
  • 黄柏酮可通过调控PROC和F2R抑制凝血、改善炎症反应;通过调控MIF、S100A9、G6PD和IL-10参与免疫反应。
  • 黄柏酮通过调控CTSG、CASP1、MAPK1、C5AR1和CASP3保护脓毒症损伤器官;通过调控CXCR2减少中性粒细胞过度迁移至炎症部位。

研究设计与关键结果

  • 研究类型:基于网络药理学与分子对接的靶点筛选研究。
  • 黄柏酮口服生物利用度为81.58%,类药性为0.57,提示成药性良好。
  • 通过SwissTargetPrediction和DRAR-CPI软件(Z'-score < -0.5)共筛选出242个潜在靶点,其中13个与脓毒症直接相关。
  • 分子对接鉴定CTSG、CASP1、S100A9、PROC、MAPK1、G6PD、IL-10、MIF、C5AR1、CASP3、CXCR2、F2R、NAMPT为潜在抗脓毒症靶点,自由结合能分别为-32.55、1.26、-30.00、300.08、-31.88、-30.29、-21.38、-30.79、16 777.84、-21.80、6 443.36、-20.38、-23.47 kJ/mol。

证据类型、等级与局限

  • 证据类型:网络药理学与分子对接研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「适用人群与场景」「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the molecular characteristics of obacunone, and to screen and identify potential targets of obacunone against sepsis.

METHODS: The pharmacological parameters and molecular characteristics of obacunone were analyzed with the aid of the Traditional Chinese Medicine Systems Pharmacology Database Analysis Platform (TCMSP). The potential targets of obacunone against sepsis were screened using SwissTargetPrediction and Drug Repositioning and Adverse Drug Reaction Chemical-Protein Interactome (DRAR-CPI) software, with a Z'-score < -0.5. The anti-sepsis targets of obacunone were selected by Online Mendelian Inheritance in Man (OMIM), Comparative Toxicogenomics Database (CTD) and Therapeutic Target Database (TTD). The anti-sepsis potential target was identified by molecular docking software.

RESULTS: The oral bioavailability of obacunone was 81.58% and the drug-likeness was 0.57 indicating that obacunone showed good drug formation. A total of 242 potential targets were screened through SwissTargetPrediction and DRAR-CPI software, 13 targets were directly related to sepsis. Cathepsin G (CTSG), caspase-1 (CASP1), S100 calcium binding protein A9 (S100A9), protein C (inactivator of coagulation factors V a and VIII a, PROC), mitogen-activated protein kinase 1 (MAPK1), glucose-6-phosphate dehydrogenase (G6PD), interleukin-10 (IL-10), migration inhibitory factor (MIF), complement C5a receptor 1 (C5AR1), caspase-3 (CASP3), CXC chemokine receptor 2 (CXCR2), thrombin receptor (F2R), nicotinamide phosphoribosyltransferase (NAMPT) were identified as the potential targets for anti-sepsis of obacunone by molecular docking software, the free binding energies were -32.55, 1.26, -30.00, 300.08, -31.88, -30.29, -21.38, -30.79, 16 777.84, -21.80, 6 443.36, -20.38, -23.47 kJ/mol, respectively.

CONCLUSIONS: Obacunone can inhibit blood coagulation and improve inflammatory response by regulating PROC and F2R. It regulates MIF, S100A9, G6PD and IL-10 to play a role in immune response. It regulates CTSG, CASP1, MAPK1, C5AR1 and CASP3 to protect sepsis-damaged organs. By regulating CXCR2, it can reduce the excessive migration of neutrophils to the site of inflammation, alleviate tissue damage. By regulating NAMPT, it improves cellular energy status, reduces oxidative stress, and protects cells from damage.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Chen Y, Liu Y, Liu C, et al. [Optimization and identification of potential targets of obacunone against sepsis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2024. PMID: 39238407. doi:10.3760/cma.j.cn121430-20231129-01019

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。